Please ensure Javascript is enabled for purposes of website accessibility

Why Corcept Therapeutics Stock Gained 27.4% in January

By Keith Noonan - Feb 13, 2018 at 5:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Corcept Therapeutics stock posted big gains in January, but the cause for celebration proved to be short lived.

What happened

Corcept Therapeutics (CORT -3.88%) stock gained 27.4% in January, according to data provided by S&P Global Market Intelligence. The company specializes in researching and creating medications for disorders associated with the steroid hormone cortisol, and indications of strong demand for its Korlym drug (used to treat symptoms associated with Cushing syndrome) and the settlement of an outstanding legal dispute appear to have been the biggest sources of share price gains last month.

So what

In August, Corcept filed a lawsuit against Dohmen Life Sciences, a company that it had contracted for pharmacy services. Corcept's suit sought damages related to a material breach of contract and release from the terms of the deal. In turn, Dohmen withheld roughly $13.2 million that it had collected from the sale of Korlym and filed its own suit claiming that Corcept had illegally terminated the contract and seeking damages and declaratory relief.

A chemical formula and molecular diagram for cortisol along with seven red pills.

Image source: Getty Images.

Corcept then published an 8-K report on Jan. 11, outlining that it had reached a settlement with Dohmen. As per the terms laid out in the deal, Dohmen agreed to pay Corcept $12.9 million. For reference, Corcept recorded $42.8 million in revenue and $13.8 million net income in its September-ended quarter, so the settlement represented a significant boon for the company. 

Now what

Unfortunately for Corcept and its shareholders, the company's big stock gains quickly reversed in February following indications that generic alternatives to Korlym would soon be available. Teva Pharmaceutical Industries (TEVA -5.41%) filed an application for a generic version of the drug on Feb. 5, prompting steep sell-offs for Corcept stock.

CORT Chart

CORT data by YCharts

Korlym is currently the only drug that Corcept has on the market, and the unexpected debut of generic alternatives would have a dramatic impact on the company's business. Corcept's management has indicated that it will pursue legal avenues to defend its intellectual property, while Teva maintains that its drug won't infringe on Korlym patents. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corcept Therapeutics Incorporated Stock Quote
Corcept Therapeutics Incorporated
CORT
$23.78 (-3.88%) $0.96
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.52 (-5.41%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.